Background
==========

Osteoporosis (OP) is a systemic bone disease that involves decreased bone density and bone quality. The destruction of the bone microstructure and an increase in bone fragility eventually lead to an increase of fracture risk and pose a serious threat to the health of middle-aged and elderly people \[[@b1-medscimonit-25-5700]\]. In terms of pathogenesis, osteogenesis-osteoclast coupling is unbalanced, with increased osteoclasts, increased lipogenesis, and decreased osteogenesis, which are closely related to proliferation and differentiation of bone marrow mesenchymal stem cells (BMSCs), hematopoietic stem cells, osteoblasts, osteoclasts, adipocytes and other cells, and involves multiple systems such as osteogenesis, hematopoiesis, and immunity. The pathogenesis of OP is complex, and there is interaction and crossover between OP and a variety of related signaling pathways. At present, conventional anti-osteoporotic drugs have disadvantages such as targeting only a single target, poor efficacy, and serious adverse effects \[[@b2-medscimonit-25-5700]\]. Therefore, an increasing number of scholars are paying attention to research on the prevention and treatment of osteoporosis using traditional Chinese medicine \[[@b3-medscimonit-25-5700]\].

Traditional Chinese medicine contains a large number of ingredients and uses extremely complex mechanisms to intervene in the progression of disease. *Rhizoma drynariae*, from the *Drynaria fortunei* dry rhizome, is a traditional Chinese medicine commonly used in orthopedics departments and widely used in the treatment of osteoporosis. Although previous studies have confirmed the efficacy of *Rhizoma drynariae* in treating OP \[[@b4-medscimonit-25-5700],[@b5-medscimonit-25-5700]\], since its ingredients are complex and its action targets numerous, it is difficult to fully elucidate its mechanism of action. Therefore, it is necessary to study the biological processes of drug, gene, and protein interactions at a systematic level to reveal the molecular mechanisms related to the efficacy of TCM ([Figure 1](#f1-medscimonit-25-5700){ref-type="fig"}).

In recent years, along with continuous innovation and the development of systems biology, network pharmacology, and computer technology, it can be seen that network pharmacology has a wide applicational value in many fields, such as drug-target identification, the discovery of effective ingredients, research on the mechanism of action, preclinical study of drug efficacy, and safety evaluation \[[@b6-medscimonit-25-5700]\]. We sought to further assess the anti-osteoporotic mechanism of *Rhizoma drynariae*, to assist in development of new drugs, and to improve conventional anti-osteoporosis drug treatments for OP defects and bottlenecks. We based our study on the concepts of network pharmacology, data searching, and data mining through the establishment of screening for *Rhizoma drynariae* active ingredients and the osteoporosis targets of the protein--protein interaction (PPI) network diagram.

Material and Methods
====================

Screening for active ingredients of *Rhizoma drynariae*
-------------------------------------------------------

According to the parameters of ADME (absorption, distribution, metabolism, excretion) \[[@b7-medscimonit-25-5700],[@b8-medscimonit-25-5700]\], we screened for the active ingredients of *Rhizoma drynariae* by searching the pharmacological database of the traditional Chinese medicine system and analyzing platforms (TCMSP) (*<http://ibts.hkbu.edu.hk/LSP/tcmsp.php>*) \[[@b9-medscimonit-25-5700]\], last updated on 2014-05-31. The screening conditions were oral bioavailability (OB) greater than 30% and drug similarity (DL) greater than 0.18 \[[@b10-medscimonit-25-5700],[@b11-medscimonit-25-5700]\]. A total of 16 active ingredients and their corresponding typical SMILES structures were obtained by searching relevant literature and the PubChem network database (*<https://pubchem.ncbi.nlm.nih.gov/>*) \[[@b12-medscimonit-25-5700]\].

Prediction of targets of the active ingredients in *Rhizoma drynariae*
----------------------------------------------------------------------

The SMILES structures of ingredients obtained from PubChem were imported into the Prediction Target of Swiss Target Prediction network database (*<http://www.swisstargetprediction.ch/>*) \[[@b13-medscimonit-25-5700]\]. Predictions can be carried out using 5 marker organisms, and predictions can be mapped using the principle of homology, within and between different species for close paralogs and orthologs. To improve prediction accuracy, only 118 predicted targets with high probability were selected and duplicates were deleted. After importing the 118 targets into the Therapeutic Target Database (TTD) (*<http://bidd.nus.edu.sg/group/cjttd/>*), Comparative Toxicogenomics Database (CTD) (*<http://ctdbase.org/>*), and PharmGKB (*<https://www.pharmgkb.org/>*), the disease target network database was used to verify whether they were related to osteoporosis. Then, Gene Ontology (GO) enrichment and Kyoto Encyclopedia of Genes and Genomes(KEGG) network pathway analysis were performed on the targets obtained. Cytoscape \[[@b14-medscimonit-25-5700]\] was used to construct Compound Target and Compound Pathway network maps for this data.

Targets associated with osteoporosis
------------------------------------

The Online Mendelian Inheritance in Man (OMIM) \[[@b15-medscimonit-25-5700]\], PubMed, and other databases were used to search for relevant research reports, and all known targets related to osteoporosis were found. "Osteoporosis" was used as the keyword to search and screen for OP-related targets, and known targets in the pathogenesis of OP were obtained. Since target names in each database are irregular, official symbols were converted into Uniprot IDs for subsequent analysis. Then, the OP related targets were imported into the DAVID database (*<http://david.abcc.ncifcrf.gov> version 6.7*) for GO enrichment and KEGG network pathway analysis.

Establishing a T-T network
--------------------------

PPI network mapping was performed on obtained bioactive ingredients and disease targets using BisoGenet software. Then, Cytoscape was used to fuse and extract the intersection of the 2 network graphs drawn, so as to obtain a direct and an indirect target-target regulatory network graph of *Rhizoma drynariae* treatment of OP. Again, along with the analysis of network topology obtained using the CytoNCA \[[@b16-medscimonit-25-5700]\] plug-in and literature, indicators such as the degree of centricity (DC), medium degree centrality (BC), close to the central (CC), the eigenvector centrality (EC), the network centricity (NC), and local edge connectivity topology selection (LAC) were used. Where nodes with a DC value greater than 2 times the median DC value of all nodes \[[@b17-medscimonit-25-5700]\] are important nodes in the network, the nodes whose other indexes are larger than the median of all nodes are termed "Big hubs" \[[@b18-medscimonit-25-5700]\]. To obtain more node information and higher node information transfer efficiency in the network as much as possible, the direct or indirect targets or mechanisms of the anti-osteoporotic effects of *Rhizoma drynariae* were further explored. The PPI network was constructed for the hub nodes obtained through the String database (*<https://string-db.org/>*) \[[@b19-medscimonit-25-5700]\]. At the same time, GO enrichment and KEGG pathway analysis were also conducted. After extensive pathways were excluded, the top 20 signaling pathways related to osteoporosis were screened out.

Molecular docking
-----------------

To further screen for the most active interactions between the active ingredients of *Rhizoma drynariae* and the key nodes, the reliability of this study was verified through computer simulation docking technology. To obtain the SDF structure of active ingredients from the PubChem database (*<https://pubchem.ncbi.nlm.nih.gov/>*), data were imported into the SystemsDock online docking software (*<http://systemsdock.unit.oist.jp/>*) \[[@b20-medscimonit-25-5700]\] for molecular docking simulation.

Results
=======

Screening of active ingredients of *Rhizoma drynariae*
------------------------------------------------------

A total of 71 reported active ingredients of *Rhizoma drynariae* were retrieved by searching the TCMSP database, and 18 of these bioactive ingredients were preliminarily screened out using ADME parameters such as OB and DL. After finding the relevant structure and target data from PubChem and the Swiss Target Prediction database, 16 active ingredients with corresponding targets were obtained after final screening, as shown in [Table 1](#t1-medscimonit-25-5700){ref-type="table"}. Most of the selected active ingredients are flavonoids such as naringin, (2R)-5,7-dihydroxy-2-(4-hydroxyphenyl)chroman-4-one, kaempferol, eriodictyol, luteolin, and a small amount of lignans and steroids such as β-sitosterol. Most of these ingredients possess potent pharmacological activity. For example, β-sitosterol has good anti-oxidation and anti-inflammatory effects \[[@b21-medscimonit-25-5700],[@b22-medscimonit-25-5700]\], luteolin has antibacterial, anti-oxidant, and other broad biological and pharmacological properties \[[@b23-medscimonit-25-5700]\], and kaempferol has an anti-inflammatory effect \[[@b24-medscimonit-25-5700]\], and naringenin was determined to be the quality markers of *Rhizoma drynariae* in the Chinese Pharmacopoeia (the State Pharmacopoeia Commission of China, 2015). The OB of these compounds varies greatly, presenting an approximately normal distribution, mostly concentrated at about 40%, and the OB is generally inversely proportional to the molecular weight (MW). The lower the MW, the higher the OB is. The route of administration of most drugs is oral. In addition to OB, the intestinal epithelial permeability (Caco-2) of the drug plays an important role in its efficacy. Overall, the higher the DL, the higher the Caco-2, such as Stigmasterol DL: 1.76, Caco-2: 1.44, luteolin DL: 0.25, and Caco-2: 0.19.

The putative target of active ingredients of *Rhizoma drynariae*
----------------------------------------------------------------

Swiss Target Prediction was used to predict the targets of 16 chemical ingredients of *Rhizoma drynariae*, and a total of 118 targets were obtained after high-possibility screening and de-duplication. We found that 50 of the 118 putative targets were common to 2 or more of these ingredients, suggesting that these ingredients act on some of the same biological processes or pathways, which reflects the synergistic effect of multiple ingredients on bone fractionation, and the targets also play an important role in the entire pathogenesis of OP. The Compound target network is shown in [Figure 2](#f2-medscimonit-25-5700){ref-type="fig"}. [Figure 3](#f3-medscimonit-25-5700){ref-type="fig"} shows the 32 KEGG enriched signaling pathways and the constructed Target-Pathway network.

OP-related targets
------------------

By searching the OMIM and PubMed databases for related research reports, we obtained 95 and 256 targets, respectively, which are closely related to the occurrence and development of OP. A total of 316 targets were screened after double checking and removal of false-positive information. Since database names are irregular, the official symbol was converted into Uniprot IDs for use in subsequent analyses. Then, the obtained OP-related targets were imported into the DAVID database for GO enrichment and KEGG network pathway analysis. By excluding a wide range of pathways from KEGG enrichment results, the following top 10 signal transduction pathways were selected: PI3K-Akt signaling pathway, osteoclast differentiation, MAPK signaling pathway, TNF signaling pathway, Rap1 signaling pathway, Ras signaling pathway, FoxO signaling pathway, thyroid hormone signaling pathway, signaling pathways regulating pluripotency of stem cells, and the Wnt signaling pathway ([Table 2](#t2-medscimonit-25-5700){ref-type="table"}).

Hub node screening and PPI network graph construction of *Rhizoma drynariae* action on OP
-----------------------------------------------------------------------------------------

Regulation within the body is usually not dominated by a single signaling pathway but rather through a complex regulatory network. Complex crossover networks usually exist between different signaling pathways and targets. Therefore, the active ingredients of a drug not only directly combine with the target, but also combine with other targets in direct and indirect ways. Therefore, the construction of the PPI network and text mining can further explore the direct or indirect regulation relationship between the active ingredients of *Rhizoma drynariae* and the regulation of OP. Through the construction of the T-T network on the predicted targets of the biological active ingredients of *Rhizoma drynariae* using BisoGenet, it can be seen that there are 5019 targets that have direct or indirect effects on them, while there are 213 839 correlations between them. There are 13 500 targets directly or indirectly related to osteoporosis, while 523 812 targets are related to each other. Using Cytoscape, the 2 T-T graphs drawn above were extracted and intersected, resulting in a total of 4421 targets and 199 264 correlations. Then, according to the topology of DC, BC, CC, EC, NC, and LAC, CytoNCA was used to obtain 97 hub nodes and 2200 relationships, including 5 putative targets of *Rhizoma drynariae* and 9 targets of osteoporosis. Among them, 2 targets were common to both and 85 targets did not belong to either, suggesting that bone fragments mainly regulate osteoporosis through indirect targets. The hub node was imported into the string to build the T-T network, as shown in [Figure 4](#f4-medscimonit-25-5700){ref-type="fig"}.

Hub node enrichment analysis of OP with *Rhizoma drynariae*
-----------------------------------------------------------

After G0 enrichment analysis of the hub node through the DAVID database (p\<0.05), a total of 139 enrichment results were obtained. These include 80 Biological processes (BP), 32 Molecular functions (MF), and 27 Cellular components (CC). The top 10 enrichment results listed in each category are shown in [Figure 2](#f2-medscimonit-25-5700){ref-type="fig"}. The top 20 related signaling pathways, after removal of the extensive pathway of KEGG pathway enrichment, are shown in [Table 3](#t3-medscimonit-25-5700){ref-type="table"}. Topological signaling pathways that coincide with OP target-related pathways or very important pathways include: PI3K-Akt signaling pathway, osteoclast differentiation, Wnt signaling pathway, estrogen signaling pathway, MAPK signaling pathway, FoxO signaling pathway, TNF signaling pathway, Thyroid hormone signaling pathway, and the cell cycle. Of these, the putative targets of 16 active ingredients of *Rhizoma drynariae* are directly involved in the estrogen signaling pathway, thyroid hormone signaling pathway, PI3K Akt signaling pathway, cell cycle, FoxO signaling pathway, MAPK signaling pathway, and other OP-related signaling pathways, involving all cells related with the occurrence of osteoporosis, such as osteoblasts, osteoclasts, adipocytes, and bone marrow stromal stem cells. These are also the mainstream pathways of clinical research and drug treatment for OP, indicating that the results of this study are reliable. The anti-OP targets of *Rhizoma drynariae* are abundant and the mechanism reliability is high ([Figure 5](#f5-medscimonit-25-5700){ref-type="fig"}).

The main active ingredients of *Rhizoma drynariae* are docked with key targets
------------------------------------------------------------------------------

In these 9 KEGG pathways, a total of 36 targets were enriched, in which TP53 frequency and connectivity were the highest. EP300 and RELA appeared frequently and were abundantly expressed in bone marrow. In recent years, the pathogenesis of oxidative stress in OP has attracted more and more attention. STAT3 not only participates in the oxidative stress FoxO pathway, but also acts as a downstream transcription factor to mediate the stress response caused by multiple pathways. The estrogen pathway and thyroid hormone pathway are the main pathways for clinical use of drugs to inhibit bone resorption and promote bone formation. ESR1 is an important target for the treatment of OP and participates in the enrichment of estrogen and thyroid receptor pathways. Osteoblast proliferation plays an important role in improving osteoporosis. CDK2 is an important kinase that regulates the cell cycle and has a high frequency in the enrichment pathway. TRAF appears in the osteoclast differentiation pathway and is upstream of the signaling pathway, which mediates multiple pathways involved in osteoporosis. Therefore, among the 9 main pathways, key targets with high repetition frequency, high clinical research value, and wide coverage were selected: CDK-2, EP300, ESR1, RELA, STAT3, TP53, and TRAF6. Molecular docking validation was conducted on all active ingredients of *Rhizoma drynariae*. The binding strength was evaluated according to the score, and the mechanism of action was predicted. Binding efficiency is shown in the table below. However, these results need further experimental verification in order to evaluate the reliability of this study and further reveal the active ingredients and the mechanism of action of *Rhizoma drynariae* ([Table 4](#t4-medscimonit-25-5700){ref-type="table"}).

Discussion
==========

The theory of traditional Chinese medicine is based on systematic medical methodology. It is difficult to fully reveal the mechanisms of the action of traditional Chinese medicine through the study of single ingredients or action targets. It is of great significance to integrate the molecular mechanism of traditional Chinese medicine used in the treatment of diseases through network pharmacology, which is based on big data bioinformatics. *Rhizoma drynariae* is one of the main drugs used in the treatment of OP with Chinese herbal medicine. The chemical ingredients isolated from *Rhizoma drynariae* mainly are flavonoids, triterpenoids, phenolic acids, and glycosides. Flavonoids such as naringin can play an anti-osteoporotic role by promoting osteogenesis and inhibiting osteoclast formation \[[@b25-medscimonit-25-5700]\], while neoeriocitrin can play a stronger anti-osteoporotic role by promoting osteogenesis \[[@b26-medscimonit-25-5700]\].

After enrichment analysis of the predicted targets of the active ingredients of the bone-crushing tonic, the main signaling pathways related to osteoporosis were found to include: nitrogen metabolism, ovarian steroidogenesis and serotonergic synapses, calcium signaling pathway, cell cycle, estrogen signaling pathway, inflammatory signaling pathways, and other pathways closely related to the occurrence and development of OP. This suggests that *Rhizoma drynariae* may have a variety of active ingredients that prevent osteoporosis through multiple pathways.

The KEGG enrichment analysis of the hub node further revealed that *Rhizoma drynariae* can regulate stem cells, osteoblasts, osteoclasts, and immune cells through multiple pathways, including proliferation, differentiation, immunity, and oxidative stress. GO enrichment analysis showed that *Rhizoma drynariae* can play an anti-osteoporotic role through the bi-directional regulation of upstream transcription processes, promoting an osteogenic differentiation of cells, and regulating cell proliferation and apoptosis, but its bi-directional regulation mechanism still needs further experimental verification. After the KEGG enrichment analysis, it was found that relevant molecular mechanisms were mainly concentrated in 3 categories of pathways related to cell proliferation and differentiation, immune, and inflammation pathways, with the main pathway being the classical Wnt signaling pathway, which plays a dual role in osteoblast and osteoclast differentiation \[[@b27-medscimonit-25-5700]\]. Increased levels of oxidative stress induced by various factors can promote osteoclast activity, inhibit osteoblastic activity, and promote apoptosis of bone cells \[[@b28-medscimonit-25-5700],[@b29-medscimonit-25-5700]\]. Experiments have proven that the FoxO pathway plays an important role in the anti-oxidative stress response of osteoblasts \[[@b30-medscimonit-25-5700]\]. However, its antagonistic Wnt signal increases with age \[[@b31-medscimonit-25-5700]\]. On one hand, the decrease in estrogen will lead to an increase of osteoclasts and osteoclastic activity; on the other hand, it can promote the secretion of inflammatory factors, such as that of the interleukin and tumor necrosis factor (TNF) family, further promoting bone resorption, and affecting the balance of the RANKL-RANK-OPG axis, leading to increased osteoclast differentiation and activation of osteoclastic activity \[[@b32-medscimonit-25-5700]\]. Rap1 is critical for resorptive function, and its selective inhibition in mature osteoclasts retards pathological bone loss \[[@b33-medscimonit-25-5700]\]. *In vivo* and *in vitro* studies indicate that the PI3K/Akt cell signaling pathway is involved in the inhibition of osteoporosis by promoting osteoblast proliferation, differentiation, and bone formation \[[@b34-medscimonit-25-5700]\]. Activated MAPK is involved in physiological processes such as cell proliferation, differentiation, migration, apoptosis, and stress response. It has been found that the ERK1/2 pathway, JNK pathway, and P38 pathway play important roles in increasing osteoblastic generation, reducing osteoclast differentiation, and anti-osteoporotic activity \[[@b35-medscimonit-25-5700]--[@b37-medscimonit-25-5700]\]. Studies have shown that thyroid hormones increase bone turnover in the body and promote osteogenesis, but stimulate bone resorption *in vitro* \[[@b38-medscimonit-25-5700],[@b39-medscimonit-25-5700]\]. The renin-angiotensin system (RAS) also plays an important role in the regulation of bone metabolism in osteoporosis \[[@b40-medscimonit-25-5700],[@b41-medscimonit-25-5700]\]. These studies all indicate that *Rhizoma drynariae* can act on OP at multiple levels through multiple mainstream signaling pathway networks that are mediated by direct or indirect targets. Furthermore, the advantages of *Rhizoma drynariae* in the treatment of osteoporosis and its potential in new drug development are further illustrated by this study.

Molecular docking is a quick method of predicting binding strength between TCM ingredients and targets based on the spatial structure of ligands and receptors. SystemsDock \[[@b20-medscimonit-25-5700]\] online docking software uses a docking score to evaluate the binding strength of molecules, and a number from 0 to 10 indicates binding strength from weak to strong. In the signaling pathway network, cross-linking or key nodes often play an important role in mediation. Through screening and integration of hub nodes, related signal pathways, and OP experimental research, we screened out CDK2, ESR1, EP300, RELA, TRAF6, TP53, and STAT3 by performing computer simulations of molecular docking in order to verify the enrichment pathway and T-T network. The docking results show that multiple active ingredients of *Rhizoma drynariae* have a tight binding strength on the hub nodes, which further indicates that the anti-OP mechanism of *Rhizoma drynariae* is diverse and active. Estrogen deficiency is the main factor leading to PMOP, and existing estrogen-like drugs are important in the treatment of OP. Genome-wide association studies have also revealed that ESR1 may be a key gene that is highly associated with osteoporosis \[[@b42-medscimonit-25-5700]\]. The docking results show that many ingredients of *Rhizoma drynariae* have high binding strength with estrogen receptors, suggesting that *Rhizoma drynariae* may have estrogen-like effects. Existing research has also confirmed that naringin in *Rhizoma drynariae* extract can promote osteogenesis through estrogen receptor stimulation \[[@b43-medscimonit-25-5700]\], which also further confirms the reliability of this study. Cyclin-dependent kinases (Cdks) are a family of serine/threonine kinases that are key regulators of transcription processes underling coordinated cell cycle entry and sequential progression in nearly all types of proliferative cells \[[@b44-medscimonit-25-5700]\], and can be combined with Cyclin. To play a role in regulating the proliferation cycle of osteoblasts, multiple active ingredients of *Rhizoma drynariae* bind tightly to CDK2, and it is speculated that this promotes osteoblast proliferation by increasing the expression of CDK2 in osteoblasts. EP300 is highly expressed in bone marrow and may be involved in the regulation of cell osteogenic differentiation and osteopenia through chromatin remodeling. It has also been found to be regulated by BMP2 and BMP7 in nucleus pulposus cells, which may be closely related to the occurrence of osteoporosis \[[@b45-medscimonit-25-5700],[@b46-medscimonit-25-5700]\]. Studies have shown that *Rhizoma drynariae* not only has an anti-OP effect, but can also improve the degeneration of nucleus pulposus cells, which can influence the expression of EP300. Increased nuclear transcription factor kappa B (NF-κB) signaling activity can induce osteoclast differentiation gene expression and increase osteoclast activity and bone resorption \[[@b47-medscimonit-25-5700],[@b48-medscimonit-25-5700]\]. RELA belongs to the NF-κB family and is abundant in bone marrow. It has been found that plastin 3 (PLS3) mutation can significantly enhance susceptibility to osteoporosis and postmenopausal osteoporosis in the elderly, while the upregulation of RELA (NFκB subunit p65) in PLS3-overexpressing mice is known to stimulate osteoclastogenesis, but strikingly reduces osteoclast resorption \[[@b49-medscimonit-25-5700]\]. Multiple ingredients of *Rhizoma drynariae* have strong binding capacity with RELA, suggesting that its mechanism of improving osteoporosis may be related to inhibiting the expression of RELA and inhibiting the activity of osteoclasts. The TRAF (TNF receptor associated factor) family of molecules, as intracellular adaptor proteins, are involved in various biological processes such as bone metabolism, immunity, and stress response. TRAF6 may be involved in inducing the activation of NF-κB, thereby promoting osteoporosis \[[@b50-medscimonit-25-5700]\]. Studies have found that TP53 plays a role in regulating tissue aging \[[@b51-medscimonit-25-5700]\], while p53 induces cell cycle arrest during aging \[[@b52-medscimonit-25-5700]\], and the activation of autophagy can restore degenerative properties of aged BMMSCs via regulating p53 expression \[[@b53-medscimonit-25-5700]\]. STAT3 is a member of the STAT family and acts as a downstream target of multiple pathways such as MAPK, MTOR, and JAK. It can be stimulated by upstream signaling molecules such as IL5, IL6, and BMP2 to act as a transcription factor to mediate the expression of various genes in cell growth and cell death. It plays a key role in the process of cell death. The activation of STAT3 can promote upregulation of Runx2 and ALP and decrease the expression of DKK1 \[[@b54-medscimonit-25-5700]\], suggesting that some active ingredients in *Rhizoma drynariae* may be specific ligands for regulating STAT3 expression.

Due to the complexity of Chinese native medicine ingredients and limitations in experimental research methods, there is at present a lack of relevant research reports on the effect of the ingredients of *Rhizoma drynariae* on the targets and its activity of treating OP alone. However, this study shows that it is valuable to use network pharmacology and molecular docking technology to screen for the active ingredients of traditional Chinese medicines and predict their relevant mechanisms of action. Multiple targets and multiple pathways that play a role in OP were used to decipher, for the first time, the possible molecular mechanisms of *Rhizoma drynariae*. This work shows the holistic characteristics of OP treated with *Rhizoma drynariae*. According to the docking results of SystemsDock, the active chemical ingredients were filtered, which provided the basis for subsequent research. The medicinal ingredients with a high score obtained by screening can provide a scientific and practical basis for the establishment of a multi-index quantitative fingerprint and improvement of the quality evaluation of compound ingredients.

Conclusions
===========

Traditional Chinese medicine itself is a mixture of complex ingredients acting on multiple targets and pathways, which makes it difficult to study the mechanism of action of the active ingredients of traditional Chinese medicines. Network pharmacology provides a new approach and ideas that are of high research significance and value for screening the active ingredients of traditional Chinese medicines. Based on bioinformatics analysis and computer simulation technology, we analyzed the active materials and the possible molecular mechanism of *Rhizoma drynariae* on OP, providing an important theoretical basis for subsequent experimental studies.
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###### 

Active Ingredients and ADME parameters of *Rhizoma drynariae*.

  No          Name                                                  Structure   OB (%)   DL
  ----------- ----------------------------------------------------- ----------- -------- ------
  MOL001040   (2R)-5,7-dihydroxy-2-(4-hydroxyphenyl)chroman-4-one               42.36    0.21
  MOL001978   Aureusidin                                                        53.42    0.24
  MOL002914   Eriodyctiol (flavanone)                                           41.35    0.24
  MOL000449   Stigmasterol                                                      43.83    0.76
  MOL000358   beta-sitosterol                                                   36.91    0.75
  MOL000422   Kaempferol                                                        41.88    0.24
  MOL004328   Naringenin                                                        59.29    0.21
  MOL000492   (+)-Catechin                                                      54.83    0.24
  MOL005190   Eriodictyol                                                       71.79    0.24
  MOL000569   Digallate                                                         61.85    0.26
  MOL000006   Luteolin                                                          36.16    0.25
  MOL009061   22-Stigmasten-3-one                                               39.25    0.76
  MOL009063   Cyclolaudenol acetate                                             41.66    0.79
  MOL009075   Cycloartenone                                                     40.57    0.79
  MOL009076   Cyclolaudenol                                                     39.05    0.79
  MOL009091   Xanthogalenol                                                     41.08    0.32

###### 

Known related targets of OP.

  LRP5        MAPK1      HLA-DQA1    SOX6      WNT3A      CRY2       CER1      TEC
  ----------- ---------- ----------- --------- ---------- ---------- --------- -----------
  TNFRSF11B   IL17A      CYP1B1      NOS1      MST1R      SLC37A4    GREM2     CASP3
  VDR         SERPINE1   NLRP3       NPY       IL37       ZYX        NMUR2     STAT5A
  COL1A1      CYP19A1    HSPA5       CDX2      MIR214     MIR503     BMP2K     IRF8
  TGFB1       GSTT1      ALDH7A1     CCNE1     PTGER4     GNPTAB     SNX10     INPP5D
  TNF         RAP1A      FGF23       WRN       PTN        FRZB       NPNT      S1PR1
  ESR1        NPPB       TYMS        SLC34A1   MTNR1B     LGMN       MIR422A   SH3BP2
  MTHFR       ICAM1      CD40        ALPL      ITGA1      GALNT3     THSD4     ZMPSTE24
  TP53        MIR21      RUNX2       ETS1      UGT2B17    LRRC4C     RNF185    TCIRG1
  IL6         HLA-A      VKORC1      POMC      PER3       TSC22D3    DCAF13    HS6ST1
  APOE        DKK1       TWIST1      SCG2      EPHB2      MIR449A    FBXO33    CYLD
  COL1A2      PIK3CA     CNR1        PTHLH     MEF2C      KDM5A      MIR2861   CRTAP
  VEGFA       HLA-DQB1   DPP4        FGF21     INSL3      PLOD1      ZNF410    ACKR1
  IGF1        CD44       MMP14       NOX4      ATF6       CA8        IL4       FUT7
  IL10        KIT        CNR2        PTK2B     SLC11A2    IL18BP     SP7       XPA
  ACE         CALCR      THBS1       SAA1      PLS3       IBSP       LMNA      MIR34C
  ADIPOQ      ADRB2      LTA         CX3CL1    MT-TL1     SPRY1      TERT      SLC26A2
  APP         CYP1A1     ANXA2       GSN       SLC1A3     FTCDNL1    IL1RN     TPH1
  BRCA1       SIRT1      GH1         TGFB2     SATB2      SLC7A7     CTSK      HRAS
  NOS3        SPP1       SHBG        JAG1      KAT2A      DOK6       ITGB2     LMNB2
  ABCB1       SOD2       IL15        WNT1      G6PC       NMU        CBS       ACTG2
  AR          BMP2       AHSG        MIR27A    LEPQTL1    SMS        IGF1      PROK2
  AKT1        MAPK3      GC          CTSK      SPP2       PUM1       CALCA     TGIF2
  BDNF        SOST       HP          ITLN1     MIR140     DANCR      BGN       RPL5
  IL1B        IGF1R      TNFRSF1B    DNM1L     COLEC10    SLC22A11   EIF2AK3   B4GALT7
  TLR4        FGF2       BGLAP       PRKAR1A   FSHB       VPS13B     TERC      MTND5
  CTNNB1      MBL2       MC4R        ALOX15    AMFR       RXFP2      RECQL2    NOG
  CXCL8       IL1A       KL          CCL20     MIR34B     QPCT       MIR34A    CAVIN1
  GSTM1       FTO        CCR2        RARRES2   SFRP4      GPR68      POLG      GPR48
  SLC6A4      CYP3A4     SPARC       SFRP1     MIR133A1   LGR4       ZAP70     RIN2
  TNFSF11     P2RX7      PTH         NOTCH2    MIR23B     GDF11      MYC       GHR
  LEP         HGF        TRPV1       CYP27B1   CSTA       TBC1D8     NOTCH1    SERPINA12
  HLA-B       RHOA       BMP4        LCT       DVL2       TSPAN12    ERCC2     TYROBP
  SLC9A3R1    ALDH2      ITGA2B      IRS2      TUBA1B     XYLT2      HDC       CA10
  MTOR        IGF2       LTF         BIRC2     CARTPT     FGFBP1     IL1R1     CCKBR
  ESR2        LEPR       SMAD2       IL16      NPY2R      LRP4       MGP       CST3
  PON1        STAT1      TRAF6       OSBPL1A   ANKH       ATP6V1H    ITGAV     
  CCL2        ALB        HSD11B1     LRP6      P2RX4      THSD7A     PPP3CA    
  BRCA2       MMP3       ADORA2A     CD47      MCM6       ARHGEF3    NFKB1     
  MMP2        CYP17A1    TNFRSF11A   PDLIM4    WNK4       SQOR       BTK       

###### 

The Top 20 enrichment pathways of 97 hub nodes.

  Term                                   Count   Value
  -------------------------------------- ------- ----------
  Cell cycle                             14      8.70E-11
  PI3K-Akt signaling pathway             14      1.80E-05
  MAPK signaling pathway                 12      1.60E-05
  Estrogen signaling pathway             10      2.30E-07
  Thyroid hormone signaling pathway      9       1.00E-05
  Osteoclast differentiation             8       1.50E-04
  Prolactin signaling pathway            7       5.10E-05
  FoxO signaling pathway                 6       8.40E-03
  TNF signaling pathway                  6       2.80E-03
  Neurotrophin signaling pathway         6       5.40E-03
  Wnt signaling pathway                  5       3.70E-02
  TGF-beta signaling pathway             5       6.90E-03
  Toll-like receptor signaling pathway   5       1.90E-02
  Jak-STAT signaling pathway             5       6.50E-02
  Notch signaling pathway                4       1.10E-02
  NOD-like receptor signaling pathway    4       1.20E-02
  B cell receptor signaling pathway      4       2.90E-02
  ErbB signaling pathway                 4       5.00E-02
  NF-kappa B signaling pathway           4       5.00E-02
  HIF-1 signaling pathway                4       6.70E-02
  T cell receptor signaling pathway      4       7.20E-02

###### 

Molecular docking between the 16 compounds of *Drynaria rhizome* and the candidate major hub targets.

  Ligand                                                Receptor   score   Ligand                    Receptor   Score
  ----------------------------------------------------- ---------- ------- ------------------------- ---------- -------
  (+)-catechin                                          CDK2       8.341   Digallate                 CDK2       6.062
  (+)-catechin                                          EP300      8.257   Digallate                 EP300      6.542
  (+)-catechin                                          ESR1       7.497   Digallate                 ESR1       6.41
  (+)-catechin                                          RELA       6.337   Digallate                 RELA       6.288
  (+)-catechin                                          STAT3      7.454   Digallate                 STAT3      7.556
  (+)-catechin                                          TP53       6.284   Digallate                 TP53       6.242
  (+)-catechin                                          TRAF6      7.137   Digallate                 TRAF6      4.934
  (2R)-5,7-dihydroxy-2-(4-hydroxyphenyl)chroman-4-one   CDK2       6.143   Eriodictyol               CDK2       8.331
  (2R)-5,7-dihydroxy-2-(4-hydroxyphenyl)chroman-4-one   EP300      6.339   Eriodictyol               EP300      8.278
  (2R)-5,7-dihydroxy-2-(4-hydroxyphenyl)chroman-4-one   ESR1       6.368   Eriodictyol               ESR1       8.072
  (2R)-5,7-dihydroxy-2-(4-hydroxyphenyl)chroman-4-one   RELA       6.099   Eriodictyol               RELA       7.835
  (2R)-5,7-dihydroxy-2-(4-hydroxyphenyl)chroman-4-one   STAT3      7.749   Eriodictyol               STAT3      4.942
  (2R)-5,7-dihydroxy-2-(4-hydroxyphenyl)chroman-4-one   TP53       6.328   Eriodictyol               TP53       4.898
  (2R)-5,7-dihydroxy-2-(4-hydroxyphenyl)chroman-4-one   TRAF6      6.532   Eriodictyol               TRAF6      2.180
  22-Stigmasten-3-one                                   CDK2       6.077   Eriodyctiol (flavanone)   CDK2       5.683
  22-Stigmasten-3-one                                   EP300      6.452   Eriodyctiol (flavanone)   EP300      6.502
  22-Stigmasten-3-one                                   ESR1       6.431   Eriodyctiol (flavanone)   ESR1       6.333
  22-Stigmasten-3-one                                   RELA       6.786   Eriodyctiol (flavanone)   RELA       7.204
  22-Stigmasten-3-one                                   STAT3      7.531   Eriodyctiol (flavanone)   STAT3      4.985
  22-Stigmasten-3-one                                   TP53       6.404   Eriodyctiol (flavanone)   TP53       4.953
  22-Stigmasten-3-one                                   TRAF6      6.408   Eriodyctiol (flavanone)   TRAF6      7.112
  Aureusidin                                            CDK2       6.013   kaempferol                CDK2       5.706
  Aureusidin                                            EP300      6.546   kaempferol                EP300      6.602
  Aureusidin                                            ESR1       6.351   kaempferol\_              ESR1       6.429
  Aureusidin                                            RELA       7.651   kaempferol                RELA       6.337
  Aureusidin                                            STAT3      4.958   kaempferol                STAT3      7.543
  Aureusidin                                            TP53       4.927   kaempferol                TP53       6.405
  Aureusidin                                            TRAF6      5.015   kaempferol                TRAF6      6.513
  beta-sitosterol                                       CDK2       8.373   luteolin                  CDK2       6.092
  beta-sitosterol                                       EP300      8.258   luteolin                  EP300      6.493
  beta-sitosterol                                       ESR1       7.602   luteolin                  ESR1       6.338
  beta-sitosterol                                       RELA       6.19    luteolin                  RELA       6.291
  beta-sitosterol                                       STAT3      7.514   luteolin                  STAT3      7.723
  beta-sitosterol                                       TP53       6.434   luteolin                  TP53       6.387
  beta-sitosterol                                       TRAF6      4.969   luteolin                  TRAF6      6.446
  cycloartenone                                         CDK2       8.367   naringenin                CDK2       8.345
  cycloartenone                                         EP300      8.351   naringenin                EP300      8.232
  cycloartenone                                         ESR1       7.842   naringenin                ESR1       7.602
  cycloartenone                                         RELA       7.85    naringenin                RELA       6.224
  cycloartenone                                         STAT3      4.961   naringenin                STAT3      7.339
  cycloartenone                                         TP53       4.946   naringenin                TP53       6.316
  cycloartenone                                         TRAF6      7.134   naringenin                TRAF6      6.258
  Cyclolaudenol acetate                                 CDK2       8.419   Stigmasterol              CDK2       6.045
  Cyclolaudenol acetate                                 EP300      8.376   Stigmasterol              EP300      6.555
  Cyclolaudenol acetate                                 ESR1       7.681   Stigmasterol              ESR1       6.652
  Cyclolaudenol acetate                                 RELA       7.853   Stigmasterol              RELA       7.385
  Cyclolaudenol acetate                                 STAT3      4.818   Stigmasterol              STAT3      4.902
  Cyclolaudenol acetate                                 TP53       4.778   Stigmasterol              TP53       4.86
  Cyclolaudenol acetate                                 TRAF6      4.974   Stigmasterol              TRAF6      4.99
  cyclolaudeno                                          CDK2       3.64    xanthogalenol             CDK2       7.291
  cyclolaudeno                                          EP300      4.538   xanthogalenol             EP300      5.738
  cyclolaudeno                                          ESR1       3.897   xanthogalenol             ESR1       6.396
  cyclolaudeno                                          RELA       3.896   xanthogalenol             RELA       7.599
  cyclolaudeno                                          STAT3      1.914   xanthogalenol             STAT3      8.323
  cyclolaudeno                                          TP53       2.917   xanthogalenol             TP53       8.514
  cyclolaudeno                                          TRAF6      4.968   xanthogalenol             TRAF6      8.075
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